Breast Cancer (Clinical Trials)

Metastatic Cancer Trial Expanded To Broader Patient Population

Published in Women's Health Weekly, April 28th, 1997

PDT, Inc., Santa Barbara, California, announced that it has expanded the Phase II/III clinical trial of SnET2 (Purlytin TM) photodynamic therapy for cutaneous metastatic breast cancer to include a broader patient population.

The study protocol has been expanded to allow patients on certain chemotherapies to participate in the trials, and also enable individuals on hormonal therapy to enter the study earlier in their treatment regimens.

"The expansion of this clinical trial gives physicians more flexibility in managing patients with this difficult disease and gives more patients the opportunity to participate in the study," said Gary S. Kledzik,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1997-04-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry